# Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

> **NCT04566952** · PHASE2 · UNKNOWN · sponsor: **Xiaoxiang Chen** · enrollment: 68 (estimated)

## Conditions studied

- Ovarian Cancer
- Ovarian and Fallopian Tube Cysts and Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Neoplasms, Female
- Urogenital Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Carcinoma, Ovarian Epithelial
- Ovarian Diseases
- Adnexal Diseases
- Genital Diseases, Female
- Carcinoma
- Anlotinib
- PARP Inhibitors
- BRCA1 Mutation
- Angiogenesis
- Antineoplastic Agents
- BRCA2 Mutation

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT04566952
- **Lead sponsor:** Xiaoxiang Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-28
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2020-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566952, "Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04566952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*